Page of

Cognitive Enhancers for Alzheimer’s Disease 

Cognitive Enhancers for Alzheimer’s Disease
Chapter:
Cognitive Enhancers for Alzheimer’s Disease
Source:
Cognitive Enhancement in CNS Disorders and Beyond
Author(s):

Po-Heng Tsai

DOI:
10.1093/med/9780190214401.003.0003

Alzheimer’s disease (AD) is the most common cause of dementia. In the United States, an estimated 5.3 million people had AD dementia in 2015, including 200,000 individuals younger than age 65 years. The number of people who are affected by AD is projected to reach 16 million in 2050. There is a tremendous cost associated with caring for people with AD. In 2015, the direct costs to US society of caring for those with AD totaled an estimated $226 billion, and if no effective disease-modifying treatments become available, this could increase to $1.1 trillion in 2050. In addition to medical costs, in 2014, caregivers of people with AD and other dementias provided an estimated 17.9 billion hours of unpaid assistance, which translates to a value of $217.7 billion. Therefore, cognitive enhancers for AD by improving cognition could address symptoms associated with AD, reduce caregiver burden, and limit health care costs.

Sign In

Copyright © 2021. All rights reserved.